Necroptosis in microglia contributes to neuroinflammation and retinal degeneration through TLR4 activation

Zijing Huang1, Tian Zhou1, Xiaowei Sun1

  • 1State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China.

Insights

Microglia necroptosis triggers retinal inflammation and neural damage. Blocking this cell death pathway with necrostatin-1 offers a potential therapy for neurodegenerative diseases and neural injury.

Area of Science:

  • Neuroscience
  • Immunology
  • Ophthalmology

Background:

  • Neuroinflammation is a key factor in neural damage and neurodegenerative diseases.
  • Microglia, retinal immune cells, play a complex role in retinal inflammation.
  • The precise mechanisms driving microglial involvement in retinal damage are under investigation.

Purpose of the Study:

  • To investigate the role of necroptosis in microglia-driven retinal inflammation and neural damage.
  • To explore necroptosis blockade as a potential therapeutic strategy for retinal neurodegeneration.

Main Methods:

  • Utilized rd1 mice and acute retinal injury models to study microglia necroptosis.
  • Administered necrostatin-1 to block necroptosis in vivo.
  • Cultured microglia were subjected to lipopolysaccharide or oxidative stress in vitro.
  • Investigated the role of Toll-like receptor 4 (TLR4) signaling in microglia necroptosis.

Main Results:

  • Microglia exhibited receptor-interacting protein kinase 1 (RIP1)- and RIP3-dependent necroptosis in both degenerative and injured retinas.
  • Necroptotic microglia released pro-inflammatory cytokines (e.g., TNF-α, CCL2), driving retinal inflammation.
  • Necrostatin-1 treatment suppressed inflammation, rescued retinal degeneration, and prevented neural injury.
  • TLR4 deficiency reduced microglia necroptosis and subsequent inflammation.

Conclusions:

  • Microglia necroptosis, triggered by TLR4 activation, exacerbates retinal neural damage and degeneration.
  • Targeting microglia necroptosis with inhibitors like necrostatin-1 presents a promising therapeutic approach for neuroinflammatory conditions affecting the retina.